Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell division cycle 37 homolog pseudogene (ENSG00000213414, also known as LOC345471) is a **nonfunctional genetic element** derived from the protein-coding cell division cycle 37 homolog gene. As a pseudogene, it results from DNA duplication or retrotransposition events followed by accumulation of disabling mutations, such as frameshifts or premature stop codons, preventing it from encoding a functional protein[1][4]. Most pseudogenes, including this one, do *not* act as therapeutic targets (such as receptors, enzymes, or transporters) and are not typically implicated in drug interactions, disease causation, or used as clinical biomarkers. Rarely, some pseudogenes may acquire secondary regulatory roles in gene expression, but these effects are generally uncommon and not well established for ENSG00000213414[1][4]. **Key points:** - **Pseudogenes** are defined by their resemblance to functional genes but their inability to produce full-length, functional proteins; they are classified as "unitary," "unprocessed," or "processed" based on how they arose in the genome[1][4]. - The term "cell division cycle 37 homolog pseudogene" indicates this genetic sequence is a **nonfunctional relic** of the gene "cell division cycle 37 homolog." - It is not recognized as a therapeutic or pharmacological target, nor is there evidence it serves as a receptor, enzyme, or any other active protein entity. - There are **no known drug interactions, mechanisms of action, or clinical biomarker roles** associated with this pseudogene. This target is thus **not a molecule of pharmacological or therapeutic interest**, and attempts to use or reference it as such would be incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell division cycle 37 homolog pseudogene.